186 related articles for article (PubMed ID: 10624968)
21. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
Matzdorff A; Voss R
Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353
[TBL] [Abstract][Full Text] [Related]
22. Role of platelet GpIIb/IIIa receptors in the modulation of platelet plasminogen activator inhibitors type-1 (PAI-1) release.
Mousa SA; Bozarth J; Forsythe M; Tsao P; Pease L; Reilly TM
Life Sci; 1994; 54(16):1155-62. PubMed ID: 8152339
[TBL] [Abstract][Full Text] [Related]
23. Platelet aggregation and fibrinogen binding in human, rhesus monkey, guinea-pig, hamster and rat blood: activation by ADP and a thrombin receptor peptide and inhibition by glycoprotein IIb/IIIa antagonists.
Cook NS; Zerwes HG; Tapparelli C; Powling M; Singh J; Metternich R; Hagenbach A
Thromb Haemost; 1993 Sep; 70(3):531-9. PubMed ID: 8259560
[TBL] [Abstract][Full Text] [Related]
24. Polyamines inhibit both platelet aggregation and glycoprotein IIb/IIIa activation.
Corona-de-la-Peña N; Uribe-Carvajal S; Barrientos-Rios R; Matias-Aguilar L; Montiel-Manzano G; Majluf-Cruz A
J Cardiovasc Pharmacol; 2005 Aug; 46(2):216-21. PubMed ID: 16044034
[TBL] [Abstract][Full Text] [Related]
25. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
Frelinger AL; Furman MI; Krueger LA; Barnard MR; Michelson AD
Circulation; 2001 Sep; 104(12):1374-9. PubMed ID: 11560852
[TBL] [Abstract][Full Text] [Related]
26. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.
Sirotkina OV; Khaspekova SG; Zabotina AM; Shimanova YV; Mazurov AV
Platelets; 2007 Nov; 18(7):506-14. PubMed ID: 17957566
[TBL] [Abstract][Full Text] [Related]
27. Surface expression of major membrane glycoproteins on resting and TRAP-activated neonatal platelets.
Simák J; Holada K; Janota J; Stranák Z
Pediatr Res; 1999 Oct; 46(4):445-9. PubMed ID: 10509366
[TBL] [Abstract][Full Text] [Related]
28. Glycoprotein IIb/IIIa inhibition attenuates platelet-activating factor-induced platelet activation by reducing protein kinase C activity.
Hu H; Zhang W; Li N
J Thromb Haemost; 2003 Aug; 1(8):1805-12. PubMed ID: 12911597
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of extra- and intracellular calcium chelation on human platelet function and glycoprotein IIb-IIIa complex stability.
Lanza F; Stierlé A; Gachet C; Cazenave JP
Nouv Rev Fr Hematol (1978); 1992; 34(1):123-31. PubMed ID: 1523093
[TBL] [Abstract][Full Text] [Related]
30. Differences between platelet and microparticle glycoprotein IIb/IIIa.
Nomura S; Suzuki M; Kido H; Yamaguchi K; Fukuroi T; Yanabu M; Soga T; Nagata H; Kokawa T; Yasunaga K
Cytometry; 1992; 13(6):621-9. PubMed ID: 1451594
[TBL] [Abstract][Full Text] [Related]
31. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
Straub A; Wendel HP; Azevedo R; Ziemer G
Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
[TBL] [Abstract][Full Text] [Related]
32. The effects of heparin, protamine, and heparinase 1 on platelets in vitro using whole blood flow cytometry.
Kozek-Langenecker SA; Mohammad SF; Masaki T; Kamerath C; Cheung AK
Anesth Analg; 2000 Apr; 90(4):808-12. PubMed ID: 10735780
[TBL] [Abstract][Full Text] [Related]
33. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
Keating FK; Whitaker DA; Sobel BE; Schneider DJ
Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
[TBL] [Abstract][Full Text] [Related]
34. The effects of nitric oxide (NO) on platelet membrane receptor expression during activation with human alpha-thrombin.
Keh D; Gerlach M; Kürer I; Seiler S; Kerner T; Falke KJ; Gerlach H
Blood Coagul Fibrinolysis; 1996 Sep; 7(6):615-24. PubMed ID: 8899151
[TBL] [Abstract][Full Text] [Related]
35. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
Peter K; Straub A; Kohler B; Volkmann M; Schwarz M; Kübler W; Bode C
Am J Cardiol; 1999 Sep; 84(5):519-24. PubMed ID: 10482148
[TBL] [Abstract][Full Text] [Related]
36. Surface-secreted von Willebrand factor mediates aggregation of ADP-activated platelets at moderate shear stress: facilitated by GPIb but controlled by GPIIb-IIIa.
Frojmovic MM; Kasirer-Friede A; Goldsmith HL; Brown EA
Thromb Haemost; 1997 Mar; 77(3):568-76. PubMed ID: 9066012
[TBL] [Abstract][Full Text] [Related]
37. The state of platelets preserved in extracorporeal circulation with a glycoprotein IIb/IIIa inhibitor.
Kondo N; Wakayama F; Suzuki Y; Fukui K; Takaya S; Fukuda I
Thromb Res; 2004; 113(5):303-10. PubMed ID: 15183042
[TBL] [Abstract][Full Text] [Related]
38. The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M
Acta Pol Pharm; 2009; 66(3):235-42. PubMed ID: 19645323
[TBL] [Abstract][Full Text] [Related]
39. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.
Peter K; Kohler B; Straub A; Ruef J; Moser M; Nordt T; Olschewski M; Ohman ME; Kübler W; Bode C
Circulation; 2000 Sep; 102(13):1490-6. PubMed ID: 11004138
[TBL] [Abstract][Full Text] [Related]
40. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]